Cipla Limited (NSE:CIPLA)
1,327.60
+35.30 (2.73%)
May 13, 2026, 3:29 PM IST
Cipla Revenue
In the fiscal year ending March 31, 2026, Cipla had annual revenue of 290.45B INR with 6.52% growth. Cipla had revenue of 77.97B in the quarter ending March 31, 2026, a decrease of -0.82%.
Revenue
290.45B
Revenue Growth
+2.24%
P/S Ratio
3.69
Revenue / Employee
9.58M
Employees
30,313
Market Cap
1.07T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 290.45B | 17.77B | 6.52% |
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
| Emcure Pharmaceuticals | 92.16B |
Cipla News
- 10 hours ago - Cipla Transcript: Q4 25/26 - Transcripts
- 11 hours ago - CIPLA Reports 54.6% Drop in Q4 Net Profit Amid Rising Costs - GuruFocus
- 12 hours ago - Cipla appoints Sushrut Kulkarni as Global Chief for Integrated Product Development - Business Upturn
- 13 hours ago - Cipla reports Rs 28,163 crore revenue for FY26 with robust growth in India and Africa - Business Upturn
- 13 hours ago - Cipla declares ₹13 dividend despite Q4 profit crash — what went wrong and should investors worry? - Business Upturn
- 13 hours ago - Cipla Q4 Results: Profit falls 55% on a YoY basis, margin contracts sharply - Business Upturn
- 16 days ago - Cohance Lifesciences Hits 20% Upper Circuit After Appointing Former Cipla CEO Umang Vohra as Chairman and Group CEO - Business Upturn
- 19 days ago - Cipla faces $100 million revenue risk as USFDA alert delays restart beyond FY27, says Macquarie - Business Upturn